NRAS and melanoma: Therefore, while BRAFV600-mutant melanoma shows improved clinical outcomes with targeted inhibitors of BRAF (e.g., vemurafenib, dabrafenib, encorafenib) and MEK (e.g., trametinib, cobimetinib, binimetinib), NRAS-mutant MM respond poorly [7], and resistance develops rapidly, even when used in combination with immune checkpoint inhibitors [8], with a majority of patients likely to die within a year of their disease.